司来帕格(Selexipag) - 药物靶点：PGI2 receptor_在研适应症：肺动脉高压，肺性高血压，动脉硬化闭塞症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

ACT-293987、NS-304、Selexipag (JAN/USAN/INN)

+ [8]

靶点

PGI2 receptor

作用机制

PGI2 receptor激动剂(前列腺素IP受体激动剂)

治疗领域

呼吸系统疾病其他疾病心血管疾病

在研适应症

肺动脉高压肺性高血压动脉硬化闭塞症

非在研适应症

继发性肺动脉高压慢性血栓栓塞性肺动脉高压肺结节病+ [3]

原研机构

Nippon Shinyaku Co., Ltd.

在研机构

Actelion Pharmaceuticals US, Inc.

强生（中国）投资有限公司

Janssen Pharmaceutica NV

+ [8]

非在研机构

爱可泰隆医药贸易（上海）有限公司Janssen-Cilag Ltd.Créapharm SAS

最高研发阶段批准上市

首次获批日期

美国 (2015-12-21),

肺动脉高压

最高研发阶段(中国)批准上市

特殊审评孤儿药 (美国)、优先审评 (中国)、孤儿药 (韩国)、临床急需境外新药 (中国)

登录后查看时间轴

结构

分子式C26H32N4O4S

InChIKeyQXWZQTURMXZVHJ-UHFFFAOYSA-N

CAS号475086-01-2

关联

74

项与司来帕格相关的临床试验

CTR20240232 / Active, not recruiting临床1期

司来帕格片人体生物等效性试验

采用单中心、随机、开放、两周期、自身交叉、单剂量给药设计进行空腹和餐后给药试验，评价湖南方盛制药股份有限公司生产的司来帕格片（司来帕格，规格：0.2 mg）与Actelion Pharmaceuticals Ltd.（爱可泰隆制药有限公司）持证，Excella GmbH & Co. KG（德国赫曼大药厂）生产的司来帕格片（司来帕格，商品名：Uptravi（优拓比）®，规格：0.2 mg）在中国健康受试者空腹和餐后状态下口服两制剂后的生物等效性及安全性，为该受试制剂注册申请提供依据。

开始日期2024-02-23

申办/合作机构

湖南方盛制药股份有限公司

CTR20234217 / CompletedN/A

司来帕格片在健康成年受试者中单次空腹状态及高脂餐后口服给药的随机、开放、两周期、两序列、交叉设计生物等效性试验

主要研究目的：研究重庆圣华曦药业股份有限公司生产的司来帕格片（规格：0.8mg）在中国健康受试者中空腹状态及高脂餐后以口服途径单次给药的药代动力学特征，并以Actelion Pharmaceuticals Ltd 持有，Excella GmbH & Co.KG 生产的司来帕格片（商品名：优拓比®；规格：0.8mg）为参比制剂，进行生物等效性评价。次要研究目的：考察司来帕格片受试制剂和参比制剂在健康受试者中的安全性。

开始日期2023-12-20

申办/合作机构

重庆圣华曦药业股份有限公司

NCT05825417 / Recruiting临床4期IIT

A Multicentre Randomised Cross-over Trial of Disease Specific Therapy in Patients With Pulmonary Arterial Hypertension (PAH) Implanted With Pulmonary Artery Pressure and Cardiac Rhythm Monitoring Devices (CardioMEMS/ConfirmRx)

The goal of this clinical trial is to evaluate the capacity of implantable/remote technology for early evaluation of drug therapies in patients with pulmonary arterial hypertension (PAH). The main question it aims to answer is whether structured changes in clinical therapy will be detectable using implanted regulatory approved devices. Participants will will be implanted with approved medical devices and will enter into a study of approved drugs to assess physiology, activity and patient reported quality-of-life (QoL) outcomes. Researchers will compare two therapeutic strategies in each individual patient to see if the study design provides enough evidence to personalise drug treatment plans

开始日期2023-06-14

申办/合作机构

Sheffield Teaching Hospitals NHS Foundation Trust

[+3]

100 项与司来帕格相关的临床结果

登录后查看更多信息

100 项与司来帕格相关的转化医学

登录后查看更多信息

100 项与司来帕格相关的专利（医药）

登录后查看更多信息

253

项与司来帕格相关的文献（医药）

2024-12-01·JOURNAL OF PEDIATRICS

Safety and Effectiveness of Selexipag in Pediatric Pulmonary Hypertension: A Retrospective Multicenter Cohort Study

Article

作者: Ivy, D Dunbar ; Rosenzweig, Erika B ; Miller-Reed, Kathleen ; Gentzler, Eliza R ; Frank, Benjamin S ; Avitabile, Catherine M ; Krishnan, Usha S ; Pan, Zhaoxing

OBJECTIVE:

To describe the safety and effectiveness of treating pediatric patients who have pulmonary arterial hypertension (PAH) with selexipag in a real-world, multi-center cohort, given that data supporting its use in pediatric PAH are sparse.

STUDY DESIGN:

We report a multi-center, retrospective, cohort study of children with PAH treated with selexipag. Demographic and clinical variables were extracted from the medical records. Clinical parameters were analyzed at 3 timepoints: pre-selexipag, 3-12 months post-selexipag, and >12 months follow-up.

RESULTS:

Eighty-seven patients were included, 32 received selexipag as add-on to background therapy, and 55 transitioned from another prostanoid. Median starting and final doses were 4.7 and 28.5 μg/kg/dose BID, respectively. Add-on patients demonstrated improved indexed pulmonary to systemic vascular resistance ratio after selexipag initiation (PVRi/SVRi, 0.62v0.53, p=0.034) with a lower average mean pulmonary artery pressure (MPAP, 46v39 mmHg, p=NS), and oxygen consumption (VO2 max 27.8v30.9 mL/kg/min, p=NS). Transition patients demonstrated stable MPAP (47v45 mmHg, p=NS) and a lower mean PVRi (10.9v8.2 Wood units*m², p=NS) but late functional worsening in some with VO2 max decreased at follow-up (26.0v19.5 ml/kg/min). Side effects were noted in 40% of the cohort but prompted discontinuation in only 2%.

CONCLUSIONS:

In a large, multi-center cohort, the oral prostacyclin agonist selexipag demonstrates favorable tolerability and effectiveness. Add-on patients demonstrated early hemodynamic improvement. Transition patients demonstrated early stability with risk of late functional worsening, highlighting the importance of ongoing monitoring.

2024-10-01·ESC Heart Failure

Pulmonary artery denervation versus conventional therapies for PAH: a systematic review and updated network meta‐analysis

Review

作者: Wei, Yongyue ; Chen, Feng ; Chen, Shao‐liang ; Pan, Zoucheng ; Kan, Jing ; Zhang, Longyao ; Wang, Xiang ; Wu, Xiaoyu

Abstract:

Aims:

A recent guideline presented by the ESC Congress in 2022 had indicated a novel therapy targeted at pulmonary artery hypertension, known as pulmonary artery denervation (PADN), which get inspired from a laboratorial trial that could lowering the pulmonary artery pressure through the intervention on the animals. Our aim is to conduct a network meta‐analysis to compare the efficacy and safety of PADN from six aspects with the current conventional therapies.

Methods and results:

According to the PRISMA guidance, databases including Ovid, ClinicalTrials.gov, Medline, Embase, and PubMed were searched from inception to 22 August 2023, along with a full assessment of the previous five meta‐analyses. Data were extracted and curated for Bayesian network meta‐analysis. The primary outcome was the change in the 6‐min walking distance (6MWD) from baseline with a secondary outcome called change in mean pulmonary artery pressure (mPAP) from baseline. The four safety outcomes included risk of clinical worsening, hospitalization, mortality and severe adverse events (SAEs). The comparison is structured on a contrast model based on 65 randomized controlled trials (RCTs) on PADN and the other conventional mainstream drugs. PADN had a better effect in improving 6MWD than Placebo (−77.76 m, 95% CI: −102.04 to −54.34 m), Macitentan (−65.32 m, 95% CI: −95.34 to −36.1 m), Bosentan (−64.5 m, 95% CI: −94.7 to −35.07 m), Iloprost (−62.66 m, 95% CI: −99.48 to −27.13 m), Oxygen (−62.42 m, 95% CI: −100.01 to −25.78 m), Treprostinil (−62.01 m, 95% CI: −89.04 to −35.61 m), Riociguat (−60.59 m, 95% CI: −86.11 to −35.98 m), Selexipag (−47.2 m, 95% CI: −85.61 to −10.19 m), Sildenafil (−44.92 m, 95% CI: −74.43 to −16.15 m), or Sitaxsentan (−39.53 m, 95% CI: −78.99 to −0.76 m). PADN had a better antihypertensive effect than placebo and showed statistical significant lower risks to induce clinical worsening and re‐hospitalization than treprostinil, riociguat, and placebo groups. No statistically significant difference in risk of mortality and severe adverse events was observed between PADN versus the other interventions.

Conclusions:

Compared with 16 types of conventional therapies and Placebo, PADN has advantage over nine single therapies and Placebo in improving 6MWD and appears to be better than two types of dual‐drug combined therapies while with no statistical significance. PADN shows a favourable antihypertensive effect on mPAP and has a lower risk to trigger clinical worsening or hospitalization, while its risk on mortality and severe adverse events is still inconclusive.

2024-10-01·EUROPEAN RESPIRATORY JOURNAL

Efficacy and safety of selexipag in patients with inoperable or persistent/recurrent CTEPH (SELECT randomised trial)

Article

作者: Channick, Richard ; Delcroix, Marion ; Easton, Valerie ; Pepke-Zaba, Joanna ; Gesang, Sophie ; Madani, Michael ; Ghofrani, Hossein-Ardeschir ; Borissoff, Julian I. ; Borissoff, Julian I ; Kim, Nick H. ; Kim, Nick H ; Richard, Dominik

Background:

SELECT was the first global randomised controlled trial of selexipag with standard of care in patients with inoperable or persistent/recurrent chronic thromboembolic pulmonary hypertension.

Methods:

SELECT was a multicentre, randomised, double-blind, placebo-controlled, parallel-group, group-sequential, phase 3 study (ClinicalTrials.gov:NCT03689244). Adults aged ≤85 years in World Health Organization Functional Class I–IV, with a 6-min walk distance of 100–450 m, were randomised (1:1) to receive selexipag (200–1600 µg twice daily titration until individual maximum tolerated dose)+standard of care or placebo+standard of care. Patients were recruited into the haemodynamic set (first 91 randomised patients to undergo right heart catheterisation (RHC); week 20) or non-haemodynamic cohort (remaining patients, no RHC required). The primary end-point was percent of baseline pulmonary vascular resistance (PVR; week 20). Safety was also assessed.

Results:

Of 321 patients screened, 128 were randomised (haemodynamic set n=91 (selexipag n=47; placebo n=44)). In the haemodynamic set, 29 (31.9%) patients had previous pulmonary endarterectomy (PEA), 20 (22.0%) balloon pulmonary angioplasty (BPA), and 14 (15.4%) both PEA and BPA; 28 (30.8%) were inoperable. The independent data monitoring committee recommended to stop the study for futility as no statistically significant difference was observed for the primary end-point (between-treatment geometric least squares mean ratio of PVR: 0.95, 95% CI 0.84–1.07; p=0.412). Adverse events were reported in 63 (98.4%) and 53 (82.8%) patients for selexipag and placebo, respectively.

Conclusions:

SELECT was discontinued for futility, as no treatment effect on the primary end-point (PVR) was observed. Safety data were consistent with the established safety profile of selexipag, with no new safety signals identified.

57

项与司来帕格相关的新闻（医药）

2024-10-21

·米内网

【市场】$15亿大品种，方盛制药冲击首仿

精彩内容日前，CDE官网显示，湖南方盛制药的司来帕格片以仿制4类报产在审。司来帕格片2023年全球销售额超过15亿美元；中国三大终端六大市场（统计范围见文末）销售额超过2亿元，其中，院内市场是主力销售渠道，院外市场则快速增长。今年以来，方盛制药已有5款新品报产在审。来源：米内网项目进度数据库司来帕格片是一种口服有效、高选择性和长效的非前列腺素类前列环素受体（IP受体）激动剂，用于治疗肺动脉高压以延缓疾病进展及降低因肺动脉高压而住院的风险。近年中国零售药店终端司来帕格片销售情况（单位：万元）来源：米内网格局数据库司来帕格片近年市场规模持续扩容，2023年，在全球销售额超过15亿美元；在中国三大终端六大市场销售额超过2亿元，其中，院内市场（公立医院终端+公立基层医疗终端）是主力销售渠道，院外市场（零售药店=城市实体药店+网上药店）则快速增长，2024年上半年同比增长超过50%。米内网数据显示，司来帕格片仅有爱可泰隆拥有生产批文，国内暂无仿制药获批，湖南方盛制药、杭州朱养心药业、重庆圣华曦药业等4家均以仿制4类报产在审，获批后视同过评。今年以来，方盛制药已有司来帕格片、养血祛风止痛颗粒、洛索洛芬钠凝胶贴膏等5款新品报产在审。其中，养血祛风止痛颗粒是公司自主研发的中药1.1类新药，用于临床治疗频繁阵发性紧张型头痛；洛索洛芬钠凝胶贴膏在2023年中国三大终端六大市场是10亿元级别重磅品种。资料来源：CDE官网、米内网数据库注：米内网《中国三大终端六大市场药品竞争格局》，统计范围是：城市公立医院和县级公立医院、城市社区中心和乡镇卫生院、城市实体药店和网上药店，不含民营医院、私人诊所、村卫生室，不含县乡村药店；上述销售额以产品在终端的平均零售价计算。如有疏漏，欢迎指正！本文为原创稿件，转载请注明来源和作者，否则将追究侵权责任。投稿及报料请发邮件到872470254@qq.com稿件要求详询米内微信首页菜单栏商务及内容合作可联系QQ：412539092 【分享、点赞、在看】点一点不失联哦

2024-10-16

·空之客

【医苑观畴】2024年三季度海外药企进展更新：强生JNJ

1 整体表现 JNJ连续两个季度医药部分收入站上$14.5b，市值也略有回升、但依然回不到$400b大关，与GLP-1双雄LLY和NOVO的距离仍然很大。三季度扣除新冠影响的收入增长为6.3%，扣除并购影响下全年EPS指引调增到9.2%，在MNC里面应该属于中规中矩的表现。 2 已上市产品自免板块正在非常微妙的转折点：Ustekinumab在高位维持，LTM累计已达到$11b，不过随着生物类似药马上进入欧洲、明年进入美国，必然到来的巨大专利悬崖让全公司时刻处在达摩克利斯之剑下；而公司力推的Guselkumab也不负厚望在奋力填补Ustekinumab身后的空档，LTM累计$3.6b；Infliximab和Golimumab两个则确实彻底失去增长动力了。肿瘤板块仍然在高歌猛进：Daratumumab上市已近十年，甚至还能维持着二阶导增速，LTM累计已达到$11.1b；Apalutamide也仍在持续爬坡中，LTM累计也达到$2.9b；Cilta-cel的产能瓶颈看起来已经基本缓解、公司明确批准Ghent工厂已经投产，单季度一跃而升至$286m，环比增长都超过50%，与Daratumumab青老配合几乎在多发性骨髓瘤领域可预期着一手遮天的局面（说老实话不太理解传奇当天大跌10%是啥情况）；Teclistamab双抗的爬坡也并不理想，连续几个环比处于停滞；Ibrutinib则持续被AZ和百济侵蚀。心血管板块里，Rivaroxaban在达峰后的衰退通道中略有反弹，但Macitentan和Selexipag两个PAH产品爬坡势头略有迟缓，单季度总算堪堪突破了$1b大关，似乎想要配得上当初$30b收购Actelion的价格仍有很大距离。传染病板块就实在没什么看头了。精神板块虽然Paliperidone早已失去增长，但Esketamine爬坡还是相当有盼头、不声不响LTM累计已接近$1b。 3 在研管线近期最靓的仔毋庸置疑是EGFR/cMET双抗Amivantamab，这个季度连续收获了两个新的批准，分别是针对EGFRm NSCLC的联用Lazertinib一线方案和联用SOC化疗二线方案，背后则MARIPOSA和MARIPOSA2两个注册临床中显著的PFS获益；值得一提的是，正是Ami的异军突起，成了康方AK112冲击EGFRm setting半路杀出的程咬金（参见【药海听涛】不及的到底是什么“预期”：康方AK-112与其他药物临床数据对比）。 JNJ在肿瘤板块寄予厚望的另一组待放之花则是膀胱灌注的Taris系列，近期则是喜忧参半：在针对BCG无响应的高风险NMIBC的二期临床SunRISe-1试验中，TAR-200单药的CR高达84%、甚至高于联用PD-1；在针对铂类不耐受的MIBC新辅助治疗的二期临床SunRISe-4试验中，TAR-200联用PD-1的ORR高达60%、CR高达42%；而在治疗MIBC的三期临床SunRISe-2试验中，TAR-200与放化疗标准治疗方案相比未能显示出优效，因而试验被终止。多发性骨髓瘤是JNJ绝对的基本盘（参见【药海听涛】强生的“遮断式”布局：BCMA×CD3双抗治疗多发性骨髓瘤获批），这个适应症的耕耘依然持续不断：围绕CD38单抗Daratumumab皮下制剂的四联方案（D-VRd）获批治疗适合移植的新发MM，治疗不适合移植的新发MM的三期临床CEPHEUS试验公布积极结果、并提交了上市申请，现在能理解Dara上市十多年来为什么销售额持续在爬坡了；此外，Carvykti也公布了治疗2L MM的三期临床CARTITUDE-4研究数据更新，在三年随访时间内对比标准PVd/DPd方案能带来45%的OS获益。自免板块最重磅的进展当属FcRn单抗Nipocalimab终于递交了BLA，终于向argenx的领先地位发起挑战，能不能值回$6.5b的票价也到了见真章的时候。诚然Ustekinumab作为自免大哥和公司台柱，专利悬崖的压力无可回避且迫在眉睫，公司颇为兴奋的点了几个填坑选手的名：IL23p19单抗Guselkumab在IBD的巨大优势，有可能带来比Ustekinumab更大的体量，虽然目前也就只到后者的40%；口服IL23R多肽药物JNJ-2113，在银屑病的一系列三期临床（包括与TYK2抑制剂头对头）和IBD的二期临床，都非常值得期待；此外还有Guselkumab和Golimumab的复方JNJ-4804，也在同时攻略IBD，似将在这一广阔适应症上形成类似MM领域的遮断之势。除此以外，值得关注的进展还包括：FGFR抑制剂Erdafitinib获得欧盟批准，PAH药物Macitentan的幼儿适应症获得欧盟批准、并向FDA递交上市申请，NMDAR拮抗剂Esketamine递交难治性抑郁症的上市申请。 JNJ凭借肿瘤和自免两大板块多年来的强势表现，不仅一直是MNC中业绩成长较为稳定的一家，而且那种对重要疾病领域“遮断式”的深耕制霸方式尤为值得学习，前有MM、后可能有IBD，外加异军突起的Ami和Taris系列，都将是支撑未来多年公司价值的基石。

并购临床3期临床2期生物类似药

2024-09-30

·FierceBiotech

Cereno's HDAC inhibitor reduces risks from pulmonary arterial hypertension in phase 2 trial

Two-thirds of patients saw a sustained reduction in their pulmonary arterial pressure. Cereno Scientific’s hypertension drug was shown to improve the risk score of 43% of patients in a phase 2 study.Of the 21 participants with pulmonary arterial hypertension (PAH), nine demonstrated an improved risk score—a measurement of the risk of death from the condition—after 12 weeks of treatment with Cereno’s histone deacetylase (HDAC) inhibitor, dubbed CS1.A further six patients reported a stable risk score, meaning 71% of patients saw their score either improve or hold steady, the Swedish biotech noted in a post-market release Friday.Two-thirds of patients saw a sustained reduction in their pulmonary arterial pressure, while a third reported an improved functional class, a term for symptoms and physical capacity.Cereno’s shares were trading up 25% on the Stockholm stock exchange at 8.72 Swedish krona on Monday afternoon local time compared to a Friday closing price of 7 krona.The trial was also a success on its primary endpoint of proving the safety and tolerability of CS1, with no treatment-related serious adverse events. No changes in liver lab values or clinically significant drug-related bleedings or decreases in platelet counts were recorded, Cereno said. The company is now looking at moving CS1 into a pivotal trial and said it will use Friday’s “encouraging results” as the basis for opening talks with regulators.“We are excited to take the next steps in our journey to make a meaningful impact for patients with PAH,” Cereno’s Head of R&D Rahul Agrawal said in the release.“The CS1-003 trial demonstrated compelling signs of clinical efficacy already over a 12-week treatment period and we expect to see additional positive impact of CS1 with longer use of our drug in patients with PAH,” Agrawal added.HDACs help regulate gene expression. The FDA has already improved four HDAC inhibitors to treat blood cancers, including Merck & Co.’s Zolinza. Cereno is hoping CS1 will have success against PAH by “targeting the root cause of the disease, aiming to reverse the pathological vascular remodeling of the small lung arteries.”PAH is a rare, rapidly progressing disease in which the blood vessels narrow in the lungs, increasing blood pressure and leading to heart failure. Johnson & Johnson dominates the PAH market with its prostacyclin receptor agonist Uptravi and the endothelin receptor agonist Opsumit.In March, Merck & Co. muscled in on the action with the approval of the activin signaling inhibitor Winrevair, which the pharma has touted as acting directly on the underlying problem that causes the disease.Despite the increasingly crowded space, Cereno claimed in its release that “existing treatment alternatives are insufficient and do not address the root cause of the disease.”

临床结果临床2期

100 项与司来帕格相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D09994	司来帕格	B01AC27	DB11362

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
肺动脉高压	美国	Actelion Pharmaceuticals US, Inc.	2015-12-21

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
肺性高血压	临床3期	白俄罗斯	Actelion Pharmaceuticals US, Inc.	2021-05-03
肺性高血压	临床3期	印度	Actelion Pharmaceuticals US, Inc.	2021-05-03
肺性高血压	临床3期	罗马尼亚	Actelion Pharmaceuticals US, Inc.	2021-05-03
肺性高血压	临床3期	韩国	Actelion Pharmaceuticals US, Inc.	2021-05-03
肺性高血压	临床3期	中国台湾	Actelion Pharmaceuticals US, Inc.	2021-05-03
肺性高血压	临床3期	乌克兰	Actelion Pharmaceuticals US, Inc.	2021-05-03
慢性血栓栓塞性肺动脉高压	临床3期	美国	Actelion Pharmaceuticals US, Inc.	2019-01-23
慢性血栓栓塞性肺动脉高压	临床3期	中国	Actelion Pharmaceuticals US, Inc.	2019-01-23
慢性血栓栓塞性肺动脉高压	临床3期	阿根廷	Actelion Pharmaceuticals US, Inc.	2019-01-23
慢性血栓栓塞性肺动脉高压	临床3期	澳大利亚	Actelion Pharmaceuticals US, Inc.	2019-01-23

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03689244 (SELECT, Pubmed \| Eur Respir J) 人工标引	临床3期	慢性血栓栓塞性肺动脉高压维持	128	Selexipag	齋壓製鑰膚鏇醖窪構鹽(遞鹽積鏇廠簾鬱鏇夢夢): Ratio = 0.95 (95% CI, 0.84 ~ 1.07), P-Value = 0.412	不佳	2024-10-01
NCT03689244 (SELECT, Pubmed \| Eur Respir J) 人工标引	临床3期	慢性血栓栓塞性肺动脉高压维持	128	Placebo		不佳	2024-10-01
NCT04435782 (RESTORE, CTgov)	临床4期	肺动脉高压	9	selexipag	積選鑰鬱製齋繭鬱願繭(選鏇觸夢獵鑰簾襯窪製) = 願廠遞築鹽網醖觸鑰繭鏇構餘鏇窪艱構鏇遞鑰 (餘積網製夢繭簾襯構獵, 憲鬱積構鏇願繭憲積鏇 ~ 淵艱鹹願夢襯鹽窪壓觸) 更多	-	2024-08-20
NCT03942211 (SPHINX, CTgov)	临床2期	肺结节病	10	Placebo	憲鬱繭獵淵壓糧製糧膚(廠艱製膚範夢鏇夢鑰範) = 顧膚網願製鑰積憲鑰膚觸壓鑰憲夢醖齋選衊膚 (壓憲艱夢遞壓蓋膚願憲, 築積製艱膚顧淵獵鑰窪 ~ 襯膚夢淵艱衊廠顧鹽鬱) 更多	-	2024-05-08
ACR2023	N/A	雷诺病 \| 系统性硬皮病	-	Prostaglandin analogs	遞選鏇獵鹽窪齋窪窪繭(衊蓋膚願壓鏇選窪糧網) = The most common adverse effects were postural hypotension, flushing, and headache 範艱鹹鬱蓋鹹繭選鏇鏇 (蓋積觸膚觸顧獵積範獵 ) 更多	-	2023-11-13
ACR2023	N/A	雷诺病 \| 系统性硬皮病	-	Placebo or active control		-	2023-11-13
NCT03689244 (SELECT, CTgov)	临床3期	慢性血栓栓塞性肺动脉高压	128	DB+selexipag (Double-blind Period: Placebo)	蓋簾遞醖衊蓋憲襯壓膚(觸繭範蓋構廠顧鹽齋艱) = 壓選鑰獵鑰齋餘構選鹹壓窪淵範簾鹹鬱淵鑰鏇 (齋襯顧壓顧艱醖餘憲獵, 鏇膚網窪糧鏇鏇鹽鑰簾 ~ 夢艱醖簾廠壓顧鏇醖衊) 更多	-	2023-08-09
NCT03689244 (SELECT, CTgov)	临床3期	慢性血栓栓塞性肺动脉高压	128	Selexipag (Double-blind Period: Selexipag)	蓋簾遞醖衊蓋憲襯壓膚(觸繭範蓋構廠顧鹽齋艱) = 夢蓋積齋壓憲衊艱蓋窪壓窪淵範簾鹹鬱淵鑰鏇 (齋襯顧壓顧艱醖餘憲獵, 築獵繭淵淵鬱鹽廠鑰製 ~ 壓繭鹹廠壓繭廠獵醖壓) 更多	-	2023-08-09
NCT01112306 (CTgov)	临床3期	肺动脉高压	709	placebo+selexipag	顧廠蓋範願選顧醖築鏇(憲衊壓積構選繭簾齋獵) = 簾憲艱鬱選鬱獵艱壓窪壓夢憲鏇淵襯鹽製構鏇 (醖餘範醖顧糧積餘膚膚, 淵鹹憲憲餘築築廠艱製 ~ 鑰艱憲齋膚膚襯襯廠遞) 更多	-	2022-09-19
RAMPHA study (ESC2022)	N/A	肺动脉高压	20	Selexipag	觸積襯願鑰醖鑰製製築(觸蓋簾淵淵鑰鏇獵齋窪) = 簾構鏇簾鹽齋壓範衊積淵齋餘觸繭廠糧簾廠願 (鏇齋網艱鹽襯夢鹹鬱壓, 1179) 更多	-	2022-05-22
NCT01112306 \| NCT01106014 (GRIPHON \| GRIPHON OL, Pubmed \| Adv Ther) 人工标引	临床3期	肺动脉高压	953	selexipag	醖齋衊製糧夢壓築製糧(窪糧憲醖鑰鏇鏇願遞餘) = 艱遞鹽鹹築艱選製艱鹹繭醖衊鹽憲鑰憲網壓製 (襯廠繭願艱襯鹽簾齋顧 ) 更多	积极	2021-10-30
EUPAS 19085 (ERS2021)	N/A	肺动脉高压	382	Selexipag	遞簾積鬱積遞蓋網襯鹹(餘顧憲齋蓋蓋鬱積鬱網) = 積遞顧鹹艱夢願憲鏇積夢艱窪鹹簾鏇襯製築觸 (鑰鏇鹹窪觸壓鏇構鏇艱 ) 更多	-	2021-09-05
GRIPHON and TRITON (ESC2021)	N/A	肺动脉高压	649	Selexipag	繭遞獵願廠觸窪製襯繭(齋夢願醖齋齋構窪製鏇): HR = 0.48 (95% CI, 0.35 ~ 0.66)	-	2021-08-30
GRIPHON and TRITON (ESC2021)	N/A	肺动脉高压	649	Placebo	繭遞獵願廠觸窪製襯繭(齋夢願醖齋齋構窪製鏇): HR = 0.48 (95% CI, 0.35 ~ 0.66)	-	2021-08-30